Vitrolife starts a company in Japan

Vitrolife starts a company in Japan

Vitrolife establishes a market organization of its own in Japan to strengthen
its position in this market, the next largest in the world with regard to the
number of infertility treatments.

“The establishment of a company of our own, with an office in Tokyo, will
markedly increase our opportunities to create closer and more effective contacts
with our customers and thereby give them even better service, something which is
crucial in the Japanese market,” says Marcus Hedenskog, Head of the newly formed
Vitrolife KK. Marcus has more than 15 years' experience of working in the
Japanese market.
Demand for infertility treatments continues to be very high in Japan, not least
due to the fact that people there are planning to have children later and later
in life, which means an increased risk of infertility and a better financial
capacity to pay for infertility treatments.  
“With the investments in the building up of local sales organizations in China
and now in Japan, we are getting closer to one of our strategic objectives, to
build up a market organization that covers all important markets and we are
significantly increasing our opportunities for even faster growth in Asia, ”says
Vitrolife's VP Marketing & Sales Nils Sellbom.     
April 24, 2009
Gothenburg
Magnus Nilsson 
CEO

Queries should be addressed to: 
Magnus Nilsson, CEO, phone +46 31 721 80 61.


________________________________________________________________________________
________________________________________________
Vitrolife is a global biotechnology/medical device Group that works with
developing, manufacturing and selling advanced products and systems for the
preparation, cultivation and storage of human cells, tissue and organs. The
company has business activities within three product areas: Fertility,
Transplantation and Stem Cell Cultivation. 
     The Fertility product area works with nutrient solutions (media),
cryopreservation products and advanced consumable instruments such as needles
and pipettes, for the treatment of human infertility. The Transplantation
product area works with solutions and systems to evaluate and maintain organs
outside the body order to select usable organs and keeping them in optimal
condition while waiting for transplantation. The Stem Cell Cultivation product
area works with media and instruments to enable the use and handling of stem
cells for therapeutic purposes. 
     Vitrolife today has approximately 150 employees and the company's products
are sold in more than 80 markets. The company is headquartered in Gothenburg,
Sweden, and there are subsidiaries in USA, Australia, France and Italy.
Production facilities are housed in Sweden and USA. 
     The Vitrolife share is listed on NASDAQ OMX Stockholm, Small Cap.
________________________________________________________________________________
________________________________________________
Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity
number 556354-3452.
Tel: +46 31 721 80 00. Fax: +46 31 721 80 90. E-mail: info@vitrolife.com.
Homepage: www.vitrolife.com.

This is a translation of the Swedish version of the press release. When in
doubt, the Swedish wording prevails.